Heart failure with supra‐normal left ventricular ejection fraction: distinct polygenic bases of an unrecognized phenotype
Authors:
- 7 September 2022
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 24 (11) , 2128-2130
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Polygenic risk scores: from research tools to clinical instrumentsGenome Medicine, 2020
- Analysis of cardiac magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated cardiomyopathyNature Communications, 2020
- Insights from physiology applied to interpretation of supranormal ejection fraction in womenEuropean Heart Journal - Cardiovascular Imaging, 2020
- Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failureNature Communications, 2020
- Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?European Heart Journal, 2019
- Genetic Risk Score for Coronary Disease Identifies Predispositions to Cardiovascular and Noncardiovascular DiseasesJACC, 2019
- Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutationsNature Genetics, 2018
- Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection FractionJAMA, 2013
- A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathyEuropean Heart Journal, 2011
- Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialThe Lancet, 2003